Phase 3 study · Prilenia · NCT07609108
Prilenia's phase 3 pridopidine study for Huntington disease
About 400 adults are planned, with half getting pridopidine capsules and half a placebo for 1 year, and nobody in the study knows which. Participants who finish that year then get pridopidine for 2 more years, including those who had the placebo.
Get an email when it adds US sites
It is enrolling now. We send an email only when it adds a US site, so you hear if one opens nearer to you. Your email is used for nothing else.
Free email alert
Hear when Prilenia's phase 3 pridopidine study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your neurologist.
1. Are you an adult between the ages of 23 and 65?
2. Did your Huntington disease signs and symptoms start, and were you diagnosed, at age 21 or older?
3. Has a genetic test shown 40 or more CAG repeats in your huntingtin (HTT) gene?
The listing says a past lab result counts, or the study can run the test at screening.4. Have you gone without VMAT2 inhibitor and antipsychotic medicines for at least the last 6 months?
VMAT2 inhibitors include tetrabenazine (Xenazine), deutetrabenazine (Austedo) and valbenazine (Ingrezza). The listing itself says it does not encourage anyone to stop these medicines only to join the study.5. Have you had a seizure at any time in the last 5 years?
6. Have you had any treatment meant to lower the mutant huntingtin protein in the past year?
7. Have you ever taken part in a gene therapy study with treatment given inside the head?
The study team also checks for these, which are easier to go over with your neurologist:
- Clear motor signs of HD (DCL of 4), a Total Functional Capacity of 7 or more and a Total Motor Score of 20 or more
- An Independence Scale score of 90% or less and a CAP100 score of 95 or more at screening
- Significant heart disease, such as a long QTcF on a heart tracing, heart rhythm problems or uncontrolled atrial fibrillation
- Medicines that prolong the QT interval within 4 weeks of the baseline visit, or pridopidine within 6 weeks or 5 half-lives before screening
- Severe liver or kidney impairment, a significant neurological disorder such as a stroke, or an active or recent cancer unless localized and resolved
- Hepatitis B, hepatitis C, HIV or another serious uncontrolled disease, or pregnancy, plans to become pregnant or breastfeeding
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
- The University of Alabama at BirminghamBirmingham, Alabama · Recruiting
- University of California, San DiegoLa Jolla, California · Recruiting
- UCLA Medical CenterLos Angeles, California · Not yet recruiting
- UC Davis Medical CenterSacramento, California · Not yet recruiting
- Georgetown UniversityWashington D.C., District of Columbia · Not yet recruiting
- University of Miami-U Health Boca RatonBoca Raton, Florida · Not yet recruiting
- University of Florida (Norman Fixel Institute for Neurological Diseases)Gainesville, Florida · Not yet recruiting
- Northwestern UniversityChicago, Illinois · Not yet recruiting
- Rush University Medical CenterChicago, Illinois · Not yet recruiting
- University of Kansas Medical CenterKansas City, Kansas · Not yet recruiting
- Hereditary Neurological Disease CentreWichita, Kansas · Recruiting
- Johns Hopkins UniversityBaltimore, Maryland · Not yet recruiting
- Massachusetts General HospitalCharlestown, Massachusetts · Not yet recruiting
- Struthers Parkinson's Center / Health Partners InstituteGolden Valley, Minnesota · Recruiting
- Columbia UniversityNew York, New York · Recruiting
- Duke UniversityDurham, North Carolina · Recruiting
- University of CincinnatiCincinnati, Ohio · Not yet recruiting
- Cleveland ClinicCleveland, Ohio · Recruiting
- The Ohio State UniversityColumbus, Ohio · Recruiting
- Oregon Health and Science University (OHSU)Portland, Oregon · Not yet recruiting
- Vanderbilt University Medical CenterNashville, Tennessee · Recruiting
- UT Health, Houston, McGovern Medical SchoolHouston, Texas · Recruiting
- University of Vermont Medical CenterBurlington, Vermont · Not yet recruiting
- EvergreenHealth Research DepartmentKirkland, Washington · Not yet recruiting
- University of WashingtonSeattle, Washington · Recruiting
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07609108.
Questions people ask about Prilenia's phase 3 pridopidine study
Is Prilenia's phase 3 pridopidine study enrolling now?
ClinicalTrials.gov lists it as recruiting, as of its last update there on 2026-11-04. Only the study team can confirm whether a particular site is still taking people.
Where are the US sites for Prilenia's phase 3 pridopidine study?
The listing names 25 US sites, in Alabama, California, District of Columbia, Florida, Illinois, Kansas and 11 other states. The full list is in the sites section of this page.
Who can join Prilenia's phase 3 pridopidine study?
About 400 adults are planned, with half getting pridopidine capsules and half a placebo for 1 year, and nobody in the study knows which. The main listed requirements are in the pre-check on this page, starting with: adult-onset HD, with signs, symptoms and a clinical diagnosis at age 21 or older. Only the study team decides who can join.
How do I contact the Prilenia's phase 3 pridopidine study team?
The listing names this contact: Prilenia Medical Information, 018575745755, MedInfo@prilenia.com. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Prilenia. This page restates the public listing in plain words, and nothing here is medical advice; talk with your neurologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07609108, last updated there 2026-11-04. Questions checked against the listing on November 10, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your neurologist about whether a study is right for you.